Continuous Glucose Monitoring Has Crossed From Diabetes Management Into the General Wellness Market

The Sensor That Was Built for Medicine and Found a Bigger Market

Continuous glucose monitors were developed and regulated as medical devices for people with diabetes whose blood glucose management requires the frequent measurements that finger-stick testing cannot practically provide at the frequency that optimal glucose control demands. The clinical case for CGM in type 1 diabetes is well-established and well-documented: the continuous glucose trace that CGM provides, typically updated every one to five minutes, allows people with type 1 diabetes and their clinical care teams to identify the glucose patterns, glycaemic variability, and time-in-range metrics that predict diabetes complications better than the HbA1c measurement that quarterly clinical visits assess. The commercial success of Abbott's FreeStyle Libre and Dexcom's G6 and G7 sensors in the diabetes market has been substantial, driven by the regulatory approvals for non-adjunctive use that allowed CGM to replace rather than supplement finger-stick testing for insulin dosing decisions, and by the reimbursement expansions in the United States, United Kingdom, and other markets that made CGM accessible to the majority of people with type 1 and an expanding population of people with insulin-treated type 2 diabetes.

The wellness market entry of CGM was initially facilitated by the regulatory status of certain CGM products in jurisdictions where the device classification did not restrict sale to prescription use. Abbott's FreeStyle Libre, whose original European CE mark did not restrict it to diabetic use, began to appear in the wellness market as non-diabetic consumers, primarily high-performance athletes, nutrition-conscious individuals, and biohackers interested in metabolic optimisation, purchased the sensors to understand their own glucose responses to food, exercise, sleep, and stress. The data that a non-diabetic person's CGM generates is qualitatively different from that of a person with diabetes: glucose values that rarely if ever exceed the diabetic range, patterns of post-meal glucose excursion whose magnitude and duration reflect dietary composition and glycaemic index, and the relationship between exercise timing, intensity, and glucose response that athletic performance optimisation can use to guide training nutrition and recovery strategies.

The Commercial Wellness CGM Pivot

The commercial formalisation of the non-diabetic CGM wellness market arrived when companies including Levels Health and Supersapiens built software platforms specifically designed to interpret CGM data for non-diabetic users whose metabolic optimisation goals differ from the clinical glucose management objectives that diabetes CGM software was designed to support. Levels Health's mobile application, which integrates with CGM sensors to provide food logging, glucose response analysis, and personalised nutrition recommendations based on the user's observed glucose responses to specific foods, created the consumer wellness product layer above the medical device hardware that transformed CGM from a clinical tool into a metabolic wellness platform. The consumer proposition of knowing your own glucose response to different foods, understanding the metabolic impact of sleep quality and stress, and optimising exercise timing relative to glucose levels is a wellness narrative whose appeal extends well beyond the diabetic population to the broader market of health-conscious consumers whose willingness to invest in health optimisation tools has created the market for continuous monitoring wearables, continuous heart rate monitoring, and the other sensor-based wellness products that CGM is joining.

Abbott's Lingo CGM, specifically developed and marketed for the non-diabetic wellness consumer market, represents the first major diabetes device company's direct commercial entry into the wellness CGM market rather than allowing non-diabetic use of a medically regulated product as an unofficial secondary market. Lingo's sensor design, its glucose interpretation framework, and its coaching content are all developed for the wellness user rather than adapted from the diabetes clinical management context, reflecting the commercial assessment that the wellness CGM market is large enough and differentiated enough from the diabetes market to justify a dedicated product development and marketing investment. Dexcom's Stelo CGM, similarly positioned for non-insulin-using diabetes and wellness use, represents the same commercial pivot from the two companies that have dominated the diabetes CGM market toward the broader consumer health market whose addressable population is orders of magnitude larger.

Top 10 Companies in Continuous Glucose Monitoring Globally

1. Abbott (FreeStyle Libre): Market leader in CGM with FreeStyle Libre 3 for diabetes management and Lingo for wellness use; its 14-day sensor wear and its reader-free direct smartphone connectivity create the user experience that has driven FreeStyle Libre to become the world's best-selling CGM and whose Lingo wellness extension creates the commercial bridge to the non-diabetic market whose addressable population expands Abbott's total addressable CGM market substantially.
2. Dexcom: US CGM company whose G7 sensor and Stelo non-prescription CGM create the clinical and wellness product portfolio; its real-time CGM with predictive glucose alerts and its integration with insulin delivery systems including the Omnipod insulin pump and multiple insulin pen systems create the diabetes management ecosystem that its clinical CGM market leadership is built on.
3. Medtronic: Medical device company with the Guardian glucose sensor integrated into its MiniMed insulin pump and closed-loop artificial pancreas system; its integrated pump-CGM system rather than standalone CGM focus creates the clinical diabetes management position that its insulin pump market leadership supports, distinguishing it from the standalone CGM providers whose sensor products serve both insulin pump users and multiple daily injection users.
4. Senseonics (Eversense): US CGM company whose implantable Eversense sensor worn under the skin for up to six months creates the long-duration CGM alternative to the surface-mounted sensors that change every seven to fourteen days; its implantable approach's six-month wear duration reduces the sensor insertion burden for users whose compliance with the biweekly sensor change routine of standard CGM affects the continuity of their glucose monitoring.
5. Levels Health: US metabolic health company providing the software platform and CGM integration for non-diabetic wellness use; its food logging, glucose response analysis, and personalised nutrition recommendations create the consumer wellness application layer that transforms CGM data into actionable metabolic optimisation guidance for non-clinical users whose glucose management goals are performance and wellness rather than disease management.
6. Supersapiens: US-European athlete metabolic monitoring company using the Abbott Libre Sense Glucose Sport Biosensor for athletic performance optimisation; its Energy Band wrist display and its glucose management coaching for endurance athletes create the sports performance CGM application whose commercial market among professional and amateur endurance athletes represents the most commercially developed non-diabetic CGM application segment.
7. NutriSense: US metabolic health company providing CGM with registered dietitian coaching for weight management and metabolic health optimisation; its professional nutrition counselling integration with CGM data creates the human-in-the-loop wellness CGM service model that differentiates it from the self-directed CGM wellness platform approach of Levels and Supersapiens.
8. January AI: US metabolic health company using CGM data combined with AI-based food database analysis to predict glucose responses without requiring continuous sensor wear; its digital twin approach that models personalised glucose responses based on a calibration CGM period creates the lower-cost metabolic health monitoring product for users whose budget or willingness to wear a sensor continuously limits their CGM adoption.
9. Veri: Finnish metabolic health company using CGM with lifestyle coaching for weight management and energy optimisation; its European market focus and its coaching-forward service model create the European CGM wellness commercial presence that US-centric wellness CGM companies have been slower to develop in the regulatory and consumer contexts that differ from the US market.
10. Signos: US weight loss and metabolic health platform using CGM to personalise nutrition and exercise recommendations; its focus on weight management as the primary consumer wellness outcome rather than athletic performance or general metabolic curiosity creates the commercial positioning that the largest consumer wellness market segment, weight management, represents for CGM wellness products.

The Clinical and Regulatory Evolution

The regulatory framework for CGM in the wellness market is evolving as the technology crosses from prescription medical device into consumer wellness product. Abbott’s Lingo and Dexcom’s Stelo received FDA clearance through the De Novo pathway as non-prescription CGM devices specifically for non-insulin-using individuals, establishing the regulatory category that allows direct-to-consumer CGM sales without a prescription while maintaining the oversight that distinguishes cleared medical devices from unregulated consumer electronics. The clinical evidence that CGM generates even in non-diabetic populations is commercially valuable to the pharmaceutical and nutrition research communities whose understanding of glycaemic response variability, the observation that the same food creates different glucose responses in different individuals, is reshaping personalised nutrition science. The companies building the largest datasets of non-diabetic CGM records with accompanying lifestyle, dietary, and outcome data are creating the research asset whose commercial value extends beyond the subscription revenue of individual CGM wellness users to the population health research, insurance underwriting, and pharmaceutical development applications whose data requirements the wellness CGM market is uniquely positioned to serve.